In Ireland, the demand for GLP-1 receptor agonist medications like Ozempic and Saxenda has skyrocketed, putting significant pressure on public health budgets. Last year, the Health Service Executive (HSE) averaged €580,000 per day on these injections through free drugs schemes—a 33% increase in patient numbers since 2023. This surge reflects broader global trends in metabolic health management, where these drugs address not just diabetes but also obesity.
But what drives this spending? Who qualifies? And how does regional variation play into access? This guide breaks down the latest HSE data, explains the clinical science behind these medications, and provides practical insights for patients navigating Ireland's healthcare system.
What Are Ozempic and Saxenda?
Both Ozempic (semaglutide) and Saxenda (liraglutide) are GLP-1 receptor agonists, a class of injectable drugs that mimic the hormone glucagon-like peptide-1 (GLP-1). Naturally produced in the gut after eating, GLP-1 signals the brain to reduce appetite, slows gastric emptying, and improves insulin sensitivity—key mechanisms for blood sugar control and weight loss.
How GLP-1 Drugs Work: The Science
Satiety signaling: GLP-1 activates receptors in the hypothalamus, promoting fullness and reducing calorie intake by 20-30% in clinical trials.
Glycemic control: They enhance insulin release while suppressing glucagon, lowering HbA1c by 1-2% in type 2 diabetes patients.
Weight loss: Trials like STEP for semaglutide show 15-20% body weight reduction over 68 weeks, far surpassing lifestyle interventions alone.
Ozempic is approved for type 2 diabetes (weekly injection, 0.25-2mg doses), while Saxenda targets weight management in adults with BMI ≥30 (or ≥27 with comorbidities; daily injection, up to 3mg). Privately, Ozempic is often used off-label for weight loss, but HSE funding is stricter.
"GLP-1s represent a paradigm shift in metabolic therapy, but access hinges on approved indications." – Clinical guidelines from NICE and EMA.
HSE Funding Rules and Eligibility
The HSE reimburses these drugs via three schemes:
- Long-Term Illness (LTI) Scheme: Free for conditions like diabetes (non-means-tested). Covers Ozempic primarily.
- Medical Card: For low-income patients; covers Ozempic (diabetes) and Saxenda (weight management).
- Drugs Payment Scheme (DPS): Caps monthly spend at €80-€90 for others; includes both drugs if eligible.
Ozempic lacks EMA approval for weight loss (Wegovy does), so HSE funds it only for diabetes. Saxenda is approved and funded for obesity. This distinction fuels private off-label use and waitlists.
Spending Breakdown: €212 Million in Under 3 Years
From January 2023 to September 2024 (corrected from source), HSE spent €212 million on Ozempic and Saxenda across schemes:
